GlassScriptPhysician profile
Hector Colon Rivera
NPI 1508132119
$22,582.99
in general payments reported to CMS, 2019-2025
13 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Addiction Psychiatry providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $14.62 · 2021: $311 · 2022: $440 · 2023: $651 · 2024: $773 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $2,176 · Travel and Lodging: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,250.00 |
| Food and Beverage | $2,175.93 |
| Travel and Lodging | $111.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20,406.70 | 2022-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $653.41 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $378.28 | 2019-2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $376.20 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $137.20 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $123.97 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $120.72 | 2021 | |
| Alkermes, INC. | $111.89 | 2019-2025 | Lybalvi, Aristada |
| Biogen, INC. | $89.96 | 2023 | |
| Almatica Pharma LLC | $71.92 | 2024-2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $41.56 | 2024-2025 | Cobenfy |
| Indivior INC. | $38.27 | 2024 | Sublocade |
| Viiv Healthcare Company | $32.91 | 2024 | Cabenuva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Colon Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.